In addition, researchers determined that participants taking retatrutide had not yet reached a weight loss plateau at 80 weeks, meaning continued treatment would likely produce further weight loss
This broader view helps us understand not just retatrutide weight loss results from studies, but how any weight loss medication is shaping your overall health picture
Tirzepatide remained the leading AOM and ADM by prescription volume and showed the largest increase in total prescribing from September to December 2025
Keywords: BMI, GLP-1 agonists, headache, idiopathic intracranial hypertension (IIH), meta-analysis Plain language summary Can a type of diabetes and weight-loss drug help with idiopathic intracranial hypertension (IIH)
Telehealth programs that bundle consultation, prescription, medication, and delivery into one monthly fee typically offer the best overall value
Sleep Apnea and Kidney Disease Separate ongoing TRIUMPH Phase 3 trials are evaluating retatrutide in patients with moderate-to-severe obstructive sleep apnea and in adults with chronic kidney disease and obesity
